ATEC Alphatec Holdings, Inc.

Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0001350653
AI RATING
SELL
78% Confidence

Investment Thesis

Alphatec demonstrates compelling revenue growth (+25% YoY) and strong gross margins (71%) indicating product-market fit in the medical device sector, but is technically insolvent with negative stockholders equity (-$5.3M) and cannot service its $573.4M debt burden from operations. Negative operating margins (-11.8%), inability to cover interest expenses (-1.9x coverage), and negative free cash flow (-$10.8M) signal the business model has not yet achieved sustainable profitability despite scale.

Strengths

  • + Strong revenue growth of +25% YoY demonstrates robust market demand and execution
  • + Exceptional gross margins of 71% indicate strong pricing power and operational efficiency in manufacturing
  • + Cash position of $139.9M provides 2-3 year operational runway at current burn rates

Risks

  • ! Negative stockholders equity of -$5.3M represents technical insolvency and indicates liabilities exceed assets
  • ! High debt load of $573.4M with negative interest coverage ratio (-1.9x) creates acute refinancing and default risk
  • ! Negative free cash flow of -$10.8M despite positive operating cash flow signals capital intensity outpaces operational cash generation
  • ! Operating losses of -$22.6M and net margin of -17.6% indicate scale is not yet driving profitability

Key Metrics to Watch

Financial Metrics

Revenue
192.1M
Net Income
-33.9M
EPS (Diluted)
$-0.22
Free Cash Flow
-10.8M
Total Assets
799.5M
Cash
139.9M

Profitability Ratios

Gross Margin 71.0%
Operating Margin -11.8%
Net Margin -17.6%
ROE N/A
ROA -4.2%
FCF Margin -5.6%

Balance Sheet & Liquidity

Current Ratio
1.90x
Quick Ratio
1.12x
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
-1.93x
Long-term Debt
573.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-07T08:02:58.839104 | Data as of: 2026-03-31 | Powered by Claude AI